Antonopoulos Ioannis M, Nahas William C, Piovesan Affonso C, Falci Renato, Kanashiro Hideki, Alvarez Gilberto A, Srougi Miguel
Division of Urology, Renal Transplant Unit, Hospital das Clínicas, University of São Paulo, São Paulo, Brazil.
Urology. 2008 Dec;72(6):1362-5. doi: 10.1016/j.urology.2008.03.041. Epub 2008 May 15.
To investigate the feasibility of radical retropubic prostatectomy (RRP) in renal transplant recipients with clinically localized prostate cancer.
A prospective protocol was established between August 2004 and November 2007. In that period, 8 patients diagnosed with localized prostate cancer were submitted to RRP, and their clinicopathologic data were reviewed.
The mean age (+/- standard deviation) at surgery was 59.6 +/- 6.7 years (range, 49-67 years). All patients had T1C tumors, except for 1 with a T2A tumor. The mean preoperative prostate-specific antigen value was 4.5 +/- 1.8 ng/mL (range, 1.6-7.0 ng/mL). The mean interval between renal transplantation and RRP was 89.9 +/- 65.1 months (range, 40-209 months). The procedure was well tolerated without major complications, and all patients were discharged on the fifth postoperative day. There was no impairment to bladder descent caused by the presence of the allograft or the ureteroneocystostomy. Urethrovesical anastomosis was easily performed in all cases in the standard manner. Blood transfusion was needed in 2 patients (1 received 2 U and another 5 U of blood). The mean operative duration was 183 +/- 29.7 minutes (range, 150-240 minutes), the mean estimated blood loss was 656 +/- 576 mL (range, 100-2000 mL), and no deterioration of graft function was observed. All patients were followed, and the mean follow-up was 10.5 months (range, 2-30 months). Prostate-specific antigen was undetectable in all cases during this time frame.
Radical retropubic prostatectomy in renal transplant patients is safe, effective, and can be easily performed in the same manner as described by Walsh, regardless of the presence of the allograft. The only necessary technical modification is the avoidance of ipsilateral lymphadenectomy to prevent damage to the transplanted organ.
探讨耻骨后根治性前列腺切除术(RRP)在临床局限性前列腺癌肾移植受者中的可行性。
于2004年8月至2007年11月制定前瞻性方案。在此期间,8例诊断为局限性前列腺癌的患者接受了RRP手术,并对其临床病理资料进行回顾。
手术时的平均年龄(±标准差)为59.6±6.7岁(范围49 - 67岁)。除1例为T2A肿瘤外,所有患者均为T1C肿瘤。术前前列腺特异性抗原的平均值为4.5±1.8 ng/mL(范围1.6 - 7.0 ng/mL)。肾移植与RRP之间的平均间隔时间为89.9±65.1个月(范围40 - 209个月)。该手术耐受性良好,无重大并发症,所有患者均于术后第5天出院。同种异体移植物或输尿管膀胱吻合术的存在未导致膀胱下降受损。所有病例均以标准方式轻松完成尿道膀胱吻合术。2例患者需要输血(1例输注2单位,另1例输注5单位血液)。平均手术时间为183±29.7分钟(范围150 - 240分钟),平均估计失血量为656±576 mL(范围100 - 2000 mL),未观察到移植物功能恶化。所有患者均接受随访,平均随访时间为10.5个月(范围2 - 30个月)。在此时间段内所有病例的前列腺特异性抗原均检测不到。
肾移植患者行耻骨后根治性前列腺切除术是安全、有效的,并且无论有无同种异体移植物,均可按照沃尔什所描述的相同方式轻松进行。唯一必要的技术改进是避免同侧淋巴结清扫,以防止对移植器官造成损伤。